Our Highly Educated and Experienced

Management Team

Tyme’s Management Brings a Deep Passion for Discovering and Developing More Effective Therapies for Treating Cancer.

Tyme Technologies, Inc.’s experienced management team has a long and successful track record of discovering and developing novel therapeutics and of leading successful entrepreneurial life sciences ventures. In addition, Tyme Technologies, Inc.’s leadership team and Board of Directors has the development and commercialization of new technologies and discoveries.

Our Executives

Steven Hoffman

Chief Executive Officer

Michael Demurjian

Chief Operating Officer

Ben Taylor

President, Chief Financial Officer

Giuseppe Del Priore, MD, MPH

Chief Medical Officer

Shabnam Stanicky

Clinical Operations Officer

Board of Directors

Tyme Inc. has put together a Board of Directors comprised of world-class business leaders and highly respected medical professionals.
Steven Hoffman

Chief Executive Officer

Michael Demurjian

Chief Operating Officer

Gerald Sokol

Associate Professor Medicine & Clinical Pharmacology

Tommy Thompson

Advisor

Paul L. Sturman

Director

David Carberry

Chairman of the Audit Committee

Timothy C. Tyson

Board Member

James Biehl

Board Member

Medical Advisory Board

Tyme Inc. has put together a Scientific and Medical Advisory Board of world-class experts in oncology, clinical treatment of cancer, cancer metabolism and the development of cancer therapeutics.
Dr. Suresh Chari

Cleveland Mayo Clinic

Giuseppe Del Priore, MD, MPH

Chief Medical Officer

William K. Oh

Special Advisor

STEVEN HOFFMAN

Chief Executive Officer

Mr. Hoffman has served as Chief Executive Officer of Tyme since its formation in July 2013 and as a a cofounder and senior leader of Tyme’s precursor, Luminant, since its formation in September 2011. In such roles and continuing with his position as Chief Executive Officer and Chief Science Officer of Tyme, Mr. Hoffman supervises the development of our product candidates. He has over 25 years experience in management and technical positions with companies in the chemistry, aerospace and laser optics fields.

Prior to the establishment of Luminant, Mr. Hoffman was a co-founder and, from 1993 to 2007, Chief Technology Officer of Mikronite Technologies Group Inc., a developer, licensor and marketer of material surfacing technologies for various manufacturing processes and applications. At Mikronite, Mr. Hoffman supervised its implementation of proprietary technology. He has received numerous patents and has pending other patent applications, including a patent and three patent applications that have been assigned to our Company. His efforts with Mikronite were recognized by The Home Depot and Lowe’s with a Best New Product award and an Innovative Technology award from the New Jersey Manufacturers Association. Mr. Hoffman attended New York University and Rutgers University with a concentration in mechanical engineering from 1980 to 1984 and continued his studies under the direct supervision of the chairman of the physics department at the University of Michigan specializing in physics and electro-optics.

MICHAEL DEMURJIAN

Chief Operating Officer

Mr. Demurjian has served as Chief Operating Officer of Tyme since its formation in July 2013 and as a a cofounder and senior leader of Tyme’s precursor, Luminant, since its formation in September 2011. In such roles and continuing with his position as Chief Operating Officer of Tyme, Mr. Demurjian leads the research teams in development, studies and data collection for our submissions to regulatory authorities, including the FDA.

Prior to the establishment of Luminant, Mr. Demurjian was a co-founder and, from 1993 to 2007, Director of Marketing of Mikronite Technologies Group, Inc., a developer, licensor and marketer of material surfacing technologies for various manufacturing processes and applications. At Mikronite, Mr. Demurjian established all marketing activities and functions, marketing research and analysis, marketing strategy, implementation planning, project, process, and vendor management, organizational management and leadership. His efforts with Mikronite were recognized by The Home Depot and Lowe’s with a Best New Product Award and an Innovative Technology Award from the New Jersey Manufacturers Association. Mr. Demurjian received a BA in Economics from New York University in 1986.

BEN TAYLOR

President, Chief Financial Officer

Mr. Taylor has been Tyme’s as President and Chief Financial Officer since April of 2017. He joined Tyme with 18 years of life sciences experience in investment banking and emerging growth companies. Most recently, he was Head of Commercial Pharma for Barclays Capital Inc. Prior to Barclays, Mr. Taylor spent ten years at Goldman, Sachs & Co., where he held a variety of roles, including Head of Emerging Pharma and Co-Head of Chinese and Southeast Asian Healthcare within the investment banking division. His career has primarily been focused on biopharmaceuticals, working as an advisor to over a hundred companies at various stages of development in more than 15 countries. Mr. Taylor has extensive experience in pharmaceutical business models, science, financing and strategic transactions. In addition to investment banking, he also spent two years at a medical diagnostic start-up leading finance and business development functions. Mr. Taylor graduated from Brown University with honors.

DR. GIUSEPPE DEL PRIORE

Chief Medical Officer

Dr. Del Priore joined Tyme Inc. after serving as the National Director of Gynecologic Oncology for Cancer Treatment Centers of America (CTCA). He also serves as the Southeastern Regional Director. Prior to CTCA, Dr. Del Priore was Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine in Indianapolis, where he directed its gynecologic oncology fellowship program and continues to teach. He previously also served as Director of Gynecologic Oncology at New York Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, as well as Assistant Director of Gynecologic Oncology at New York University School of Medicine. Giuseppe Del Priore, MD, MPH has been involved with drug, device and procedure development his entire career. He has participated and been on the advisory boards of studies for most major pharmaceutical companies. An industry KOL, his opinions have earned him invitations to present at the FDA and other regulatory agencies. His work has been reported on the front pages of the NY Times, WSJ and nearly every media outlet. He has been the principle investigator on several world firsts including breakthroughs in oncology, fertility and other areas of science. Dr. Del Priore remains a sought after clinician bringing relevant insights from actual patient challenges directly to the board room. Dr. Del Priore earned his Doctor of Medicine with Distinction in Research from State University of New York Downstate Medical Center in Brooklyn. He studied at The City University of New York’s Brooklyn College in a combined Bachelor of Arts/Doctor of Medicine Program, earning both degrees in seven years. Dr. Del Priore graduated magna cum laude with a Bachelor of Arts in Philosophy and was valedictorian of his medical school class. He received his Master of Public Health in Biostatistics and Epidemiology from the University of Illinois at Chicago and completed other training at Northwestern University and the University of Rochester. 

U.S. News and World Report named Dr. Del Priore one of its “Best Doctors” in 2011 and 2012.

He is an active researcher and prolific writer. He has authored and published more than 170 papers, book chapters and abstracts and written three books. Dr. Del Priore has received two patents and has others pending. He has served on several committees and organizations, including current appointments at the Society of Gynecologic Oncologists; and previously the Gynecologic Oncology Group, a National Cancer Institute Cooperative Group. He is also an examiner for the American Osteopathic Association Board of Obstetrics and Gynecology, Gyn Oncology sub-specialty section. In his free time, Dr. Del Priore has given back to his community by serving as a volunteer physicians part of the National Association of Free and Charitable Clinics; a volunteer firefighter in Westchester County, New York; an auxiliary police officer with the New York Police Department; and a volunteer ambulance driver with the Bay Ridge Ambulance Volunteer Organization.

Shabnam Stanicky

Clinical Operations Officer

Mrs. Stanicky joined the Tyme team in January 2017 as Clinical Operations Officer. She will be focused on overseeing the operational delivery of the current and upcoming clinical trials conducted by Tyme. With over 16 years experience in clinical oncology research operations, Mrs. Stanicky has extensive experience in the management, design, execution and evaluation of clinical trials for cancer therapies. She joins Tyme from Quintiles, where she has worked since 2008 as a Clinical Operations Manager within the Oncology therapeutic area, with specific expertise within Phase I trials. She has managed both field based operational delivery as well as project based operations in her prior roles. Prior to that, Mrs. Stanicky worked for seven years performing and managing clinical oncology research at Eli Lilly and Co. and two years at the John Wayne Cancer Institute in Santa Monica, California.

GERALD SOKOL MD, MSC, FCP

Associate Professor Medicine & Clinical Pharmacology

Gerald H. Sokol MD, MSc, FCP attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine with a Masters Degree in Pharmacology and an MD. Dr. Sokol interned in Medicine at Temple University and attended the US Public Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins, and the University of Maryland completing training in Internal Medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology attaining Board Certification in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He Is also certified in Skin Cancer Medicine from the University of Queensland. Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital, has built or contributed to building over 10 highly successful cancer centers. He is a board member and partner of Florida Cancer Specialists and Research Institute (the largest research group in Florida) consisting of over 190 physicians).

Dr Sokol is a decorated retired Captain in the US Navy and served as Commanding Officer of the unit at the Uniformed Services University. Dr. Sokol currently holds professorships in Medicine and Pharmacology at that institution. While maintaining a busy medical practice Dr. Sokol served on the review staff of the FDA for over 27 years as a senior regulatory scientist and officer composing over 300 white papers, IND and NDA reviews, and opinion papers. Dr. Sokol has authored or coauthored over 100 books, book chapter, abstracts and papers on a multitude of clinical issues. He is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology. He has a busy teaching and research schedule and enjoys spending time with grand children and family.

TOMMY THOMPSON

Advisor

Tommy G. Thompson currently is the Chairman and Chief Executive Officer of Thompson Holdings, and former United States Health and Human Services (HHS) Secretary and four-term Governor of Wisconsin. Governor Thompson, through his work at Thompson Holdings, continues to develop innovative solutions to the health care challenges facing American families, businesses, communities, states and the nation as a whole. These efforts focus on improving the use of information technology in hospitals, clinics and doctors’ offices; promoting healthier lifestyles; strengthening and modernizing Medicare and Medicaid; and expanding the use of medical diplomacy around the world.

From 2005 until 2009, Governor Thompson served as a senior advisor at the consulting firm Deloitte LLP and was the founding independent chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. From 2005 to early 2012, Governor Thompson served as a senior partner at the law firm of Akin, Gump, Strauss, Hauer, & Feld LLP. Governor Thompson served as Chairman of the Board of Directors of Logistics Health, Inc. from January 2011 to May 2011, and served as President from February 2005 to January 2011. He currently serves on the Board of Directors of the following public companies: Physicians Realty Trust and TherapeuticsMD, Inc., each as Chairman of the Board of Directors, Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc., TherapeuticsMD, Inc. and United Therapeutics Corporation.

TIMOTHY C. TYSON

Board Member

Timothy Tyson is currently Chairman and CEO of Avara Pharmaceutical Services and Chairman at Icagen Inc. He currently serves on the board of Tyme Technologies Inc. and Marken LLC. Mr. Tyson recently served as Chairman and CEO of Aptuit LLC. He was Chairman and CEO from 2008 to 2012 leading a restructuring, acquisition and successful sale of a major portion of the company prior to stepping out as CEO to serve and guide the company as Chairman up until 2016.  His corporate career spans over 30 years in the pharmaceutical industry. His expertise in leadership and management is internationally recognized. From 2002-2008, Mr. Tyson served as COO, President and CEO of Valeant Pharmaceuticals International. During this period, sales grew 69% and earnings increased 135%. He led a major restructuring of the company and established a highly effective Research and Development capability which developed a best in class epilepsy compound, Potiga, which was approved in 2010, and a promising pro-drug for hepatitis C.

Prior to joining Valeant, Mr. Tyson ran multiple divisions for GlaxoSmithKline and was a member of the Corporate Executive Team. During his 14-year tenure at GlaxoSmithKline, he was President, Global Manufacturing and Supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals. Mr. Tyson was also responsible for managing all sales and marketing for GlaxoWellcome’s U.S. operations, where he launched 32 new products, eight of which reached sales of greater than $1 billion/year. Mr. Tyson held executive positions in technical operations and R & D, at Bristol-Myers from 1980-1988. Prior to his tenure at Bristol-Myers, he was a manufacturing manager at Procter & Gamble. He served on active duty as an officer in the United States Army from 1974-1979 and spent 14 years in the United States Army Reserves.

Mr. Tyson is a 1974 graduate of the United States Military Academy at West Point. While on active duty at Ft. McClellan, AL, he earned a Master of Public Administration, in 1976, and a Master of Business Administration, in 1979, from Jacksonville State University. In 2002, Mr. Tyson received a Bicentennial Leadership Award from the United States Military Academy at West Point and was named 2007 Alumnus of the Year at Jacksonville State University.

He has served on the board of directors for Valeant Pharmaceuticals International; the Pharmaceutical Research and Manufacturing Association (PhRMA); BIOCOM; on the CEO Roundtable for the University of California at Irvine; on the Dean’s Executive Forum at Cal State Fullerton; the CEO Roundtable on Cancer; the Health Sector Advisory Board at Duke University; the  International Leadership Forum of the International Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. Mr. Tyson has served on the board of directors for non-profit organizations in Raleigh-Durham, NC and Orange County, CA and with the United Way.

Paul L. Sturman

Director

Paul is a proven, entrepreneurial, global executive with 30+ years of success in delivering exceptional results in consumer driven businesses as measured by revenue and income growth, market share, organizational development and shareholder value. Recognized as a disciplined, decisive, and authentic leader that builds businesses through insight, clear strategic vision, prioritization of effort, and attracting and inspiring diverse teams to produce superior results. An intelligent risk-taker and change agent with a history of turning businesses around, creating and sustaining conditions for meaningful innovation, and transforming organizations organically and/or through M&A integration.

Paul Sturman was recently President and CEO of NJOY, Inc., a leading independent electronic nicotine delivery system company. NJOY’s mission was to end smoking-related death and disease by offering preferred alternatives to adult smokers and vapers around the world.

Paul joined NJOY in January ’15, after six years of successfully leading Pfizer’s $3+ billion Consumer Healthcare business, one of the largest over-the-counter (OTC) healthcare products companies in the world. He served as Global President and was responsible for all aspects of the business unit’s operations, including the development and marketing of major household brands such as Advil®, Centrum®, Emergen-C®, Caltrate®, ChapStick®, and Robitussin®. Previously, Paul had served as President, North America for J&J, where he was responsible for more than 30 brands including Listerine®, Band-Aid®, Stayfree®, Monistat®, Rogaine®, Neosporin®, and Visine®. He began his career with Warner-Lambert, stewarding brands like Trident sugarless gum and Halls Cough drops.

Over the past 25 years, Paul has dedicated his life to helping people feel better. He has held leadership positions in marketing and sales where he built brand strategies for leading consumer brands and OTC therapies. In all his roles, Paul has been a champion of consumer access to innovative self-care products.

A well-regarded executive in the industry, Paul served as Chairman of the Consumer Healthcare Products Association (CHPA) from 2009-11. CHPA is a not-for-profit association representing the makers of over-the-counter medicines and promoting the role of non-prescription medicines in America’s healthcare system through science, education, and advocacy.

Paul is also committed to giving back to the community. He is a member of the Board of Trustees of the Foundation for Morristown Medical Center. The Foundation works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine.

Paul earned his Bachelor’s degree in Biology and his Master’s degree in Business Administration from Bucknell University.

DR. SURESH CHARI

Cleveland Mayo Clinic

Suresh Chari, M.D. is a Professor of Medicine with the Mayo Clinic College of Medicine. He is also a consultant in the Division of Gastroenterology. He is Head of the Pancreas Interest Group in the Division of Gastroenterology and Hepatology. Dr. Chari has a broad interest in diseases of the pancreas and his NIH-funded research focuses on the role of diabetes and hyperglycemia as a marker of undiagnosed pancreatic cancer. Additional areas of clinical research involve understanding the clinical spectrum of autoimmune pancreatitis and he is also interested in cystic tumors of the pancreas including their classification, prevalence and natural history.

David Carberry

Chairman of the Audit Committee

David Carberry is a retired healthcare financial executive with over 40 years of experience in the industry. Most recently, from April 2012 to June 2016 Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. Prior to that, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company, for three years. Mr. Carberry also served in a number of financial oversight roles within Johnson & Johnson and related divisions between 1981 and 2008, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, a joint venture, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider.

James Biehl

Board Member

Jim Biehl has been a partner at the law firm of Drinker Biddle & Reath LLP in Princeton, NJ since 1989 in the Corporate and Securities group. As a corporate lawyer with over 25 years of experience representing public and private companies with structuring, negotiating and managing sophisticated securities and corporate transactional matters, he has extensive experience with federal and state securities laws, public debt and equity financings, mergers and acquisitions, corporate venture transactions, joint ventures and strategic alliances, emerging company formation and management, and corporate governance matters. Jim’s industry experience includes representing big pharma, healthcare systems, healthcare consulting firms, consumer products, and medical device companies.

William K. Oh

Special Advisor

William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute.

Clinical Interests: Management of genitourinary malignancies, including prostate, renal, bladder, adrenocortical and testicular cancers.

Research Interests: Dr. Oh’s research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer.

Another major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh’s recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.